小児周期性嘔吐症候群におけるライフスタイルとSSRIの介入:第一線管理の再考
Cansu Altuntaş1, Doğa Sevinçok2, Merve Hilal Dolu3
1Pediatric Gastroenterology, Medical Faculty, Istinye University, Istanbul 34510, Türkiye.
Children (Basel, Switzerland)
|August 28, 2025
まとめ
ライフスタイルの変化とSSRIは,小児循環嘔吐症候群 (CVS) を効果的に管理します. ライフスタイルの順守は成功を予測し サイプロヘプタジンを上回ります
科学分野:
- 小児胃腸内科
- 子どもの精神科
背景:
- 循環性嘔吐症候群 (CVS) は,繰り返し吐き気と嘔吐を伴う機能的消化器疾患である.
- 幼児のCFSには 標準的な治療法がありません ライフスタイルや不安が原因です
- トリガーの体系的な管理は,現在の小児CVS治療に完全に統合されていません.
研究 の 目的:
- 小児のCVS管理のためのライフスタイル変更とSSRIを評価する.
- ライフスタイル/SSRI介入の結果と標準的なサイプロヘプタジン予防を比較する.
- 治療の成功における不安と生活習慣の役割を評価する.
主な方法:
- CVS (ローマIV基準) と診断された119人の小児患者の遡及研究.
- 臨床的,精神的,ライフスタイルに関するデータ
- 治療法によってグループ化される患者: サイプロヘプタジン,SSRI,または急性発作管理.
主要な成果:
- 78. 2% の患者で不安が認められ,中度から重度の症例ではSSRIが100% の成功率を達成した.
- ライフスタイルの順守 (73. 9%) は治療の成功を予測した.
- ライフスタイルの変更に比べて,シプロヘプタジンは追加的な効果を示さなかった.
結論:
- ライフスタイルの介入は小児のCVSの結果を大幅に改善します.
- SSRIは,併発性不安や不適合性のあるCVSに対する安全で効果的な選択肢です.
- 精神社会やライフスタイルの戦略を 標準的な小児CVS治療プロトコルに統合する.
関連する概念動画
Irritable Bowel Syndrome III: Medical and Nursing Management
294
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
294
Gastroesophageal Reflux Disease II: Clinical Features and Management
156
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
156
Antidepressant Drugs: MAOIs and Other Agents
340
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
340
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
563
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
563
Drugs for Treatment of Diarrhea-Predominant IBS
292
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
292
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
395
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
395


